Plant Name: Cratoxylum cochinchinense
Taxonomic Information:
Plant ID: NPO24928
Plant Latin Name: Cratoxylum cochinchinense
Taxonomy Genus: Cratoxylum
Taxonomy Family: Hypericaceae
Plant External Links:
NCBI TaxonomyDB:
271749
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Thailand; China; IndiaTraditional Medicine System:
Indian Folk; TCMGeographical Distribution:
India; China; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ALOX12; IDH1; ALOX15; USP2; | |
| PTGS1; PTGS2; | |
| NFKB1; RELA; | |
| MAPT; | |
| FASN; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | IDH1 | Isocitrate dehydrogenase [NADP] cytoplasmic | O75874 | CHEMBL2007625 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | RELA | Nuclear factor NF-kappa-B p65 subunit | Q04206 | CHEMBL5533 |
| Transferase | FASN | Fatty acid synthase | P49327 | CHEMBL4158 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 5.894E-10 | 1.426E-06 | ALOX12, ALOX15, CYP19A1, CYP2C19, CYP2C9, FASN, IDH1, PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.457E-08 | 2.115E-05 | CYP19A1, CYP2C19, CYP2C9, PTGS1, PTGS2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.468E-08 | 4.422E-05 | ALOX12, ALOX15, CYP19A1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.327E-07 | 1.256E-04 | ALOX12, ALOX15, PTGS2 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.181E-07 | 2.845E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 4.181E-07 | 2.845E-04 | PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.181E-07 | 2.845E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.254E-06 | 6.660E-04 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.254E-06 | 6.660E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.254E-06 | 6.660E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.408E-06 | 7.300E-04 | CYP19A1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.325E-06 | 1.684E-03 | CYP19A1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0046890; regulation of lipid biosynthetic process | 3.626E-06 | 1.795E-03 | FASN, IDH1, NFKB1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 4.177E-06 | 1.935E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:2000630; positive regulation of miRNA metabolic process | 4.177E-06 | 1.935E-03 | NFKB1, RELA |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.262E-06 | 2.726E-03 | CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 6.386E-06 | 2.726E-03 | FASN, IDH1, MAPT, NFKB1, PTGS2, RELA |
| BP | GO:0032501; multicellular organismal process | GO:0045075; regulation of interleukin-12 biosynthetic process | 8.764E-06 | 3.534E-03 | NFKB1, RELA |
| CC | GO:0032991; macromolecular complex | GO:0033256; I-kappaB/NF-kappaB complex | 8.764E-06 | 3.534E-03 | NFKB1, RELA |
| BP | GO:0009987; cellular process | GO:0071316; cellular response to nicotine | 1.168E-05 | 4.542E-03 | NFKB1, RELA |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.876E-05 | 6.923E-03 | CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019371; cyclooxygenase pathway | 2.292E-05 | 8.318E-03 | PTGS1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.749E-05 | 9.655E-03 | CYP2C19, CYP2C9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.168E-12 | 9.343E-11 | CYP2C9, ALOX15, ALOX12, CYP2C19, PTGS2, PTGS1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.477E-11 | 1.791E-09 | CYP2C9, ALOX15, ALOX12, CYP2C19, PTGS2, PTGS1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 7.446E-09 | 1.986E-07 | CYP2C9, FASN, IDH1, ALOX15, ALOX12, PTGS2, CYP2C19, CYP19A1, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 7.763E-07 | 1.553E-05 | CYP2C9, ALOX15, CYP2C19 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 1.300E-05 | 2.080E-04 | PTGS2, RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 2.128E-05 | 2.432E-04 | PTGS2, RELA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 4.448E-05 | 3.954E-04 | PTGS2, RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.844E-05 | 2.432E-04 | CYP2C9, CYP2C19, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 2.691E-05 | 2.691E-04 | PTGS2, RELA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 5.330E-04 | 2.959E-03 | MAPT, RELA, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.694E-04 | 2.959E-03 | PTGS2, CYP19A1 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 4.508E-04 | 2.959E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 5.889E-04 | 2.959E-03 | PTGS2, PTGS1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 5.680E-04 | 2.959E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 6.100E-04 | 2.959E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 8.172E-04 | 2.959E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 6.100E-04 | 2.959E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09162 Immune diseases | hsa05321 | Inflammatory bowel disease (IBD) | 7.927E-04 | 2.959E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 8.672E-04 | 2.959E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04623 | Cytosolic DNA-sensing pathway | 7.686E-04 | 2.959E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 9.716E-04 | 2.959E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 7.927E-04 | 2.959E-03 | RELA, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 8.928E-04 | 2.959E-03 | CYP2C9, CYP2C19 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 9.986E-04 | 2.959E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 9.986E-04 | 2.959E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.914E-03 | 4.351E-03 | PTGS2, NFKB1, RELA |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 9.187E-04 | 2.959E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.899E-03 | 4.351E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.479E-03 | 3.945E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04622 | RIG-I-like receptor signaling pathway | 9.187E-04 | 2.959E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.648E-03 | 4.254E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 1.862E-03 | 4.351E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 1.054E-03 | 3.011E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 1.382E-03 | 3.813E-03 | RELA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.974E-03 | 4.351E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 2.012E-03 | 4.351E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 2.089E-03 | 4.398E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 2.012E-03 | 4.351E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 2.207E-03 | 4.528E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 2.580E-03 | 5.080E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 2.667E-03 | 5.080E-03 | RELA, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 3.608E-03 | 6.274E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 3.215E-03 | 5.933E-03 | RELA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.667E-03 | 5.080E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 3.409E-03 | 6.060E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.916E-03 | 6.666E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 3.263E-03 | 5.933E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 4.182E-03 | 6.970E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 5.573E-03 | 9.099E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 5.760E-03 | 9.216E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 5.886E-03 | 9.234E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 6.338E-03 | 9.567E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 6.208E-03 | 9.550E-03 | RELA, NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; |
| NA: NA | Rheumatold arthritis | NA | PTGS1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; |
| NA: NA | Miosis during ocular surgery | NA | PTGS1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
